Lawrence Saubermann, MD
Gastroenterology · Rochester, NYNPI 1740210939
Payments from drug & device makers
Across 58 payments — averaging $3726.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$55K
- Pfizer$53K
- Genentech, Inc.$48K
- Janssen Research & Development, LLC$37K
- AbbVie$15K
- Boehringer Ingelheim$4K
- plus $3K from 2 others
Across 8 payments — averaging $149.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Travel & lodging$1,42280%
- Food & beverage$34820%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $55,386 |
| Pfizer(2 entities) | 11 | $52,824 |
| Genentech, Inc. | 18 | $48,059 |
| Janssen Research & Development, LLC | 6 | $37,493 |
| AbbVie | 5 | $15,457 |
| Boehringer Ingelheim | 2 | $4,277 |
| Merck | 13 | $1,770 |
| Boehringer Ingelheim RCV GmbH & Co KG | 2 | $842 |
How this compares
$216,108 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 33 | $869,631 |
| CholestyramineCholestyramine (With Sugar) | 17 | $945 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Rochester
- Jonathan WilmotRochester$984K
- Jonathan GoldsteinRochester$963K
- Jonathan HuangRochester$633K
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Igor GrosmanBrooklyn$2.8M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.